Donald E. Bobo, Jr. Sells 5,000 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Trading Down 0.6 %

Shares of Edwards Lifesciences stock opened at $66.15 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a 50-day simple moving average of $67.42 and a two-hundred day simple moving average of $76.44. The company has a market cap of $39.02 billion, a P/E ratio of 9.55, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 EPS. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently bought and sold shares of EW. Point72 Hong Kong Ltd acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $66,000. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth approximately $30,000. B&L Asset Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth $3,101,000. Erste Asset Management GmbH purchased a new stake in Edwards Lifesciences in the third quarter valued at $1,298,000. Finally, Maverick Capital Ltd. acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $1,953,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Oppenheimer restated an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Canaccord Genuity Group reduced their price target on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, UBS Group decreased their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.